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ABSTRACT 
 
Iron deficiency (ID) is a common problem among US children but diagnosis 
requires four tests.  An equation using only the logarithmic ratio of circulating transferrin 
receptor to ferritin has been proposed to quantify body iron in adults, however, its 
application in children is limited.  Our objective was to determine the body iron of 
middle-class US toddlers using this equation and to compare calculated body iron to 
dietary and anthropometric covariates previously associated with ID. Eighty-six healthy, 
18-to 36-month-old toddlers were recruited. Anthropometric, dietary, and hematological 
data were collected.  Multiple regression analyses revealed dietary calcium intake and 
body mass index negatively influenced body iron, and birth weight, dietary iron intake, 
and energy intake positively influenced body iron. These predictive variables are similar 
to previously reported iron status risk factors.  Our findings support the use of the body 
iron equation as a simple measure of iron status in healthy young children. 
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CHAPTER 1: INTRODUCTION 
 
Summary of Relevant Research 
 Iron deficiency (ID) and iron deficiency anemia (IDA) are two of the most 
common nutritional deficiencies among children and women worldwide (1).  Recent data 
from of the National Health and Nutrition Examination Survey (NHANES) IV 
demonstrated that the prevalence of ID in US toddlers ages 1 to 3 years decreased from 
9% to 8% in the last decade.  Among toddlers with ID, a disproportionate number were 
overweight and did not attend day care (2). In 2006, the Pediatric Nutrition Surveillance 
System (PedNSS) as part of the National Centers for Disease Control and Prevention 
estimated the national ID prevalence to be 14.0% of children under the age of 5 years (3).  
Approximately 9.4% and 17.5% of children in Kansas and Missouri, respectively, met the 
criteria for ID (4). 
The effects of ID even at an early age may be widespread and long-lasting.  
Specifically, infants and children with ID and IDA are thought to have impaired 
neurodevelopment, decreased language ability, and poorer fine-motor skills compared 
with their iron-replete counterparts (5-6). These adverse effects may or may not be 
reversible as a result of the timing and duration of deficiency (7-9).  
Dietary habits during infancy and the transition to table foods are known to affect 
iron status.  Compared to formula fed infants, infants fed breast and cows’ milk at 8 
months of age have poorer iron status at 12 months (10), and infants who are breast fed 
exclusively over 6 months of age may be at increased risk for IDA (11). In children aged 
 2
12 to 24 months, cows’ milk, calcium, cheese, and butter intake were negatively 
associated with iron status (12-15) whereas iron, vitamin C, fish, and meat intake were 
positively associated with iron status (12, 15). 
Traditionally ID and IDA are diagnosed using a battery of laboratory measures 
including ferritin, transferrin saturation (TS), free erythrocyte protoporphyrin (FEP), and 
hemoglobin (Hgb) (16).  Iron deficiency is diagnosed if two of the first three indicators 
are abnormal.  Iron deficiency anemia is diagnosed if the criterion for ID is met and Hgb 
is low.  Critics cite the limited specificity and sensitivity of these measures along with 
their tendency to be elevated during chronic disease, inflammation or infection as 
evidence for the need to find better indicators (18-20). 
A more recent development in the detection of subclinical ID that is not subject to 
these limitations includes measurement of circulating transferrin receptor (TfR) (21-22). 
A soluble truncated form of cellular TfR, circulating TfR is primarily affected by cellular 
ID and the subsequent up-regulation of cellular TfR synthesis (23).  It is also a marker 
and valuable measure of erythropoiesis (24).  Circulating TfR is directly proportional to 
the total body mass of cellular TfR (25). 
In 1990, Skikne, Flowers, and Cook completed the hallmark study supporting the 
use of circulating TfR in the detection of subclinical ID (26). During repeated 
phlebotomies of 14 healthy adult subjects, they observed serum ferritin levels dropped 
significantly during the initial phase of storage iron depletion while serum TfR and other 
markers of iron status remained stable. When iron stores were depleted, the subnormal 
levels of serum ferritin did not change but serum TfR concentration increased 
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dramatically. In fact between storage iron depletion and the development of anemia, the 
only significant change in blood marker status occurred in serum TfR concentration.  
Their results also supported the use of serum TfR and serum ferritn in tandem to establish 
a serum TfR:ferritin ratio.  The ratio has since been logarithmically transformed and has 
been proposed as part of an equation to predict milligrams iron per kilogram body weight 
(27-28). 
Vazquez Lopez et al. stated that circulating TfR has an advantage over traditional 
measures in pediatrics because it is sensitive, specific, shows little variability, and its 
concentration can be determined from small quantities of serum (29). To date several 
studies have examined the usefulness of circulating TfR, ferritin and the circulating 
TfR:ferritin ratio in children.  As a whole, these studies report circulating TfR is higher in 
children compared to adults and is not influenced by disease state or gender (30-33).  
  
Justification for Further Investigation 
There are several gaps in the current literature regarding circulating TfR, ferritin, 
and the use of the recent total body iron equation in young populations.  For example, 
studies outside the US have determined circulating TfR concentrations in infants less than 
12 months old and young children 3 to 7 years old, but the number of studies examining 
circulating TfR in US toddlers aged 18 to 36 months is limited.  Also, although the total 
body iron equation has been reported as a suitable measure for quantifying the iron status 
of adults, quantitative phlebotomy studies have not been done to confirm its use in 
children and few studies have explored its validity as a measure of childhood ID and 
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IDA.  Specifically, no known studies have compared total body iron to dietary and 
anthropometric covariates previously associated with ID. 
 
Statement of Purpose 
 The objectives of this study are to: a) determine the current iron status of children 
aged 18 to 36 months in the Kansas City metropolitan area using plasma ferritin, plasma 
TfR, and calculated total body iron, b) identify dietary and/or anthropometric risk factors 
that relate to total body iron, and c) compare significant dietary and anthropometric risk 
factors with those previously related to ID as a means of assessing the validity of total 
body iron in toddlers.  
 
Research Questions 
1. What is the current iron status of young children aged 18 to 36 months in the 
Kansas City metropolitan area using plasma ferritin and plasma TfR to 
calculate total body iron? 
2. What significant correlations exist between hemoglobin, plasma ferritin, 
plasma TfR, total body iron, and dietary and anthropometric measures in this 
population? 
3. Do relationships between total body iron and dietary and anthropometric 
measures support the assessment of total body iron as a meaningful measure 
of iron status in toddlers? 
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Thesis format 
 The format of the following chapters is different than a traditional thesis.  Chapter 
2 will consist of a complete literature review, but rather than separate chapters for 
methods, results, and discussion, all three will be combined with a shorter introduction in 
Chapter 3. 
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CHAPTER 2:  REVIEW OF LITERATURE 
 
 The objectives of this study are to: 1) determine total body iron in middle-class 
US toddlers using plasma transferrin receptor (TfR) and plasma ferritin concentrations 
and 2) compare total body iron to dietary and anthropometric covariates previously 
associated with ID.  The following review of literature includes the history, classification, 
prevalence, hematological indicators, clinical presentations, and influential factors of Iron 
Deficiency (ID) and Iron Deficiency Anemia (IDA).  Other causes of anemia including 
anemia of chronic disease as well as B12 and folate deficiency will not be discussed. 
 
History of Iron Deficiency and Iron Deficiency Anemia 
 Similar to other nutritional deficiency diseases, ID and IDA were not originally 
attributed to diet insufficiency. The first modern description of hypochromic anemia was 
reported by Johann Lange in 1554 (1).  Lange described a girl as weak and noted, “her 
face which in the last years was distinguished by rosiness of cheeks and redness of lips, is 
sadly paled…the heart trembles with every movement of her body…her stomach loathes 
food, particularly meat”. Termed, morbus virgineus, the disease Lange wrote of was 
thought to be caused by retained menstrual blood.  The treatment was to “live with men 
and copulate” and recovery would occur with conception (2). 
 Sixty years later, in 1615, the term chlorosis replaced morbus virgineus to reflect 
the greenish tint of skin these patients exhibited.  Its reference to a gynecologic disease, 
however, did not diminish.  A successful English physician, T. Sydenham, classified 
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chlorosis as a hysterical disease coming from the word hysteron meaning uterus.  Similar 
to Lange’s treatment, Sydenham’s followers recommended marriage as the best remedy 
for this mental disease.  It was later noted Sydenham recommended “mineral water 
impregnated with the Iron Mine” not because he knew iron was an important constituent 
of blood, but because he thought his patients were weak and iron was a symbol of 
strength (1). 
 In later years, physicians strayed from the use of iron as a cure for chlorosis.  In 
1872, a French clinician named A. Trousseau noted, “The palpitations of the heart, 
spasms of the stomach, intestine, and uterus must mean chlorosis is derived from a 
nervous system disorder” (3).  Also in 1872, a German physician, R. Virchow, attributed 
the disease to congenital hypoplasia of the heart and blood vessels.  Building upon this 
idea, English physician A. Clark suggested the disease was aggravated by wearing tight 
corsets that displaced abdominal organs, obstructed the bowel, and allowed buildup of 
toxic substances in the blood (1). 
 It was not until 1895 that another physician related chlorosis to dietary iron (4).  
R. Stockman discovered patients with chlorosis on average consumed less iron than 
healthy subjects.  He concluded excessive menstrual loss together with habitually low 
dietary iron intake caused the disease. His theory, however, was not well accepted, 
because at that time the absence of a substance was not thought to cause disease. 
 At the end of the nineteenth century, scientific interests shifted yet again and the 
diagnosis of chlorosis nearly disappeared (4).  The idea of anemia and poor iron status, 
however, was not forgotten and in the late 1920s a scientist by the name of Helen 
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Mackay made the first definite conclusions about ID and IDA.  Mackay scientifically 
tracked hemoglobin (Hgb) levels in infants and noted that concentrations are high at birth 
but drop after 6 months of age (5). She also discovered low Hgb is more common and 
severe in non-breast-fed infants and low birth weight babies.  Supplementation with iron 
salts produced dramatic changes and Mackay documented a 50% reduction in respiratory 
tract infections, diarrhea, and specific fevers among supplemented infants.   Her 
recommendation that iron should be given to non-breast fed infants from the first months 
of life stands today. 
 
Classification of Iron Deficiency and Iron Deficiency Anemia 
 The progression from ID to IDA is commonly described using three stages (6).  
The first stage, termed iron depletion, represents the time when stored body iron 
decreases but functional iron status is unchanged.  If uncorrected, this stage progresses to 
iron deficient erythorpoiesis and the continued loss of stored iron impairs the synthesis of 
functional iron compounds.  The final stage, iron deficient anemia, is characterized by 
Hgb concentrations that fall below the lower limit of normal as a result of the now severe 
deficit of iron.   This last stage is commonly classified as a microcytic hypochromic 
anemia because of the abnormally small red blood cells that are light in color. 
Traditionally ID and IDA are diagnosed using a combination of transferrin 
saturation (TS), free erythrocyte protoporphyrin (FEP), ferritin, and Hgb (7-8).  The 
reference values for young children are listed in Table 1.  An individual is iron deficient 
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if any 2 of the first 3 values are abnormal for age.  An individual has IDA if the ID 
criterion is met plus Hgb is low. 
 
 
 
TABLE 1 Reference limits for ID and iron IDA in young children 
Indicator   1-2 years 3-5 years 
Transferrin Saturation  <10% <12% 
RBC Erythrocyte Protoporphyrin  >1.42 μmol/dL >1.24 μmol/dL 
Ferritin  <10 μg/L <10 μg/L 
Hemoglobin   <11.0 g/dL <11.1 g/dL 
 
 
Prevalence of Iron Deficiency and Iron Deficiency Anemia 
 The World Health Organization estimates all cause-anemia affects approximately 
2 billion people worldwide (9).  In developing countries high rates are attributed to 
insufficient dietary intake, infectious disease, other micronutrient deficiencies, or 
inherited conditions such as thalassaemia. 
 In the United States, rates are much lower and mostly reflect insufficient dietary 
iron intake.  Results from the third National Health and Nutrition Examination Survey 
(NHANES III) (1988-1994) found 9% of US toddlers ages 1 to 2 had ID and 3% had 
IDA (7).  The more recent NHANES IV (1999-2002) data revealed the prevalence of ID 
decreased to 8%; however, IDA could not be measured because of insufficient sample 
size (10).  In 2006, the Pediatric Nutrition Surveillance System (PedNSS) as part of the 
National Centers for Disease Control and Prevention observed an estimated national ID 
prevalence of 14.0% in children under the age of 5 years (11) with approximately 9.4% 
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and 17.5% of children in Kansas and Missouri affected respectively (12). Despite recent 
decreases in incidence, ID in children remains a national public health issue. The 
reduction of ID to less than 5% of 1 to 2 year olds and 1% of 3 to 4 year olds is currently 
a  Healthy People 2010 objective (13). 
 
Hematological Indicators of Iron Deficiency and Iron Deficiency Anemia 
Common measures of iron status include: Hgb, ferritin, serum iron, TS, FEP, 
mean corpuscular (MCV), and total-iron-binding capacity (TIBC).  By grouping these 
indices, an overall picture of iron status is thought to be attained; however, it is well 
documented that most of these measures are affected by various physiological states and 
laboratory constraints.  These conditions include infection, disease, gender, age, body 
size, tobacco use, alcohol use, exercise habits, contraceptive pill use, and available 
laboratory and economic resources (14-15).  Also, the sensitivity of each to detecting the 
range of ID and IDA has been questioned (16).  Ferritin, for example, decreases only 
during storage iron depletion while Hgb decreases much later during functional iron 
depletion (17). Serum iron and TS are affected by diurnal fluctuations (18), TIBC has low 
specificity (16), and most indicators aside from ferritin and Hgb require a large sample of 
blood for analysis.  
 More recently, circulating transferrin receptor (TfR) has been employed as an iron 
status marker (19).  Uninfluenced by disease state and relatively easy to obtain and 
analyze, circulating TfR has begun to replace traditional measures. Also because of its 
ability to provide a more complete picture of iron status between the depletion of ferritin 
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and Hgb, the combination of Hgb, ferritin, and circulating TfR may be useful. For the 
purpose of this review, only Hgb, ferritin, and circulating TfR will be discussed in detail. 
Hemoglobin is a three-dimensional molecule composed of two globulin chains 
and four heme groups (20).  It is embedded in the red blood cell and is vital for the 
transport of oxygen and carbon dioxide.  Based on this important role, Hgb is the primary 
functional iron compound in the body.  Changes in Hgb concentration occur only in the 
latest stage of ID denoting the onset of IDA.  Blood Hgb is often measured because of its 
low cost, ease of testing, and usefulness for establishing the presence of IDA. Normal 
adult levels vary depending on gender; however, this is not the case in children and 
reference limits are 11.0g/dL and 11.1g/dL for children 1-2 years and 3-5 years 
respectively (8).  
Opposite of Hgb, ferritin is the main iron storage compound in the body (21).  
The cellular form, synthesized by smooth endoplasmic reticulum, is thought to be 
concentrated in the liver, spleen, and bone marrow.  A small amount may be found and 
measured in circulating plasma (22-23).  Although the cellular form stores more iron, few 
other differences between the circulating and cellular molecules exist.  It is estimated that 
1μg/L of plasma ferritin represents approximately 120μg of storage iron per kilogram of 
body weight in children (21). Ferritin may be quantified in either plasma or serum and 
levels are commonly measured to assess body iron storage.  Ferritin is one of the first 
hematological markers to change during iron depletion (17) and extremely low 
concentrations (<12ug/L in adults and <10ug/L in children) are one indicator of ID and 
IDA.  In some populations ferritin is an inaccurate representation of iron status because it 
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is an acute phase reactant and may be falsely elevated.  These conditions include acute 
and chronic infections, inflammatory diseases, malignancies, liver disorders, smoking, 
exercise, alcoholism, and contraceptive pill use (14-16). 
Circulating TfR has only recently been measured as an indicator of subclinical ID.  
Discussion of a possible cellular TfR started in the 1960s, but it was not until the 1980s 
that the structure of the transferrin receptor was described (24).   In 1984, Schneider et al. 
reported cellular TfR a transmembrane glycoprotein that exists as two identical subunits 
linked by disulfide bonds. (25) When iron-loaded transferrin approaches the cell, 
transferrin binds to the receptor and receptor-transferrin complex is internalized.  Once in 
the cell, the iron is released from transferrin and the receptor returns back to the cell 
surface. Approximately 80% of cellular TfR is in the erythroid marrow; however, 
virtually all cells have cellular TfR (24). 
 In 1987, a scientist by the name of Y. Kohgo first detected a circulating form of 
cellular TfR in human serum using an immunoradiometric assay (19).  In 1989 an 
enzyme-linked immunosorbent assay (ELISA) was developed, (26) and in 1990 it was 
discovered that the circulating TfR is the same as the cellular TfR but truncated and 
bound to transferrin (27).  Either serum or plasma can be used for the measurement of the 
receptor. The prime determinant of circulating TfR concentration is cellular iron 
deficiency, and it is well accepted that circulating TfR concentration is inversely related 
to ferritin in adults (28).  Circulating TfR is also affected by erythropoesis in bone 
marrow (29-30). Circulating TfR has an advantage over other iron indices in that it is not 
an acute phase reactant and remains stable during inflammation (31).  This means that 
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measurements of circulating TfR in combination with Hgb make it possible to distinguish 
IDA from anemia of chronic disease.   
 The hallmark study for supporting the use of circulating TfR as a means of 
detecting subclinical ID was done by Skikne, Flowers, and Cook in 1990 (17).  In this 
study, serial phlebotomies were performed in 6 male and 8 female volunteers ranging 
from 24 to 46 years of age.  The end point of phlebotomy was considered the point when 
the individual’s serum Hgb levels had fallen 2 g from their baseline mean and stayed that 
way for at least 3 weeks.  A variety of hematological markers, including serum iron, TS, 
Hgb, TIBC, FEP, MCV, serum ferritin, and serum TfR were evaluated throughout the 
process.  Results indicated serum ferritin concentration fell dramatically until storage 
depletion whereas all other iron status markers were unchanged. After overt anemia was 
developed, all markers differed from their baseline value except FEP.  However, between 
the period of iron depletion and anemia, the only significant change in iron status 
occurred in serum TfR levels.  This suggests circulating TfR is the best indicator of iron 
status between the time of ID and IDA. 
 Based on the observation that ferritin reflects changes in iron storage while 
circulating TfR reflects changes in functional iron, Skikne et al. suggested a ratio of 
circulating TfR:ferritin could provide a log-linear relationship to iron storage (17).  The 
utility of the circulating TfR:ferritin ratio was confirmed when it was shown that the ratio 
of an iron supplemented group of Jamaican women was significantly different from a 
group that was not supplemented (28,32).  
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Two major advantages of using the ratio have been reported.  1) The total number 
of measures required for diagnosis of ID is far less compared to traditional measures.  
This creates fewer burdens on participants and requires less laboratory work.  2) Only 
microliters of blood are needed compared to the milliliters required for the other tests.   It 
should be noted the circulating TfR:ferritin ratio could be susceptible to the fluctuations 
seen in ferritin during inflammation and some support its use in combination with an 
inflammatory marker such as C-reactive protein (33).   
Since the discovery of circulating TfR, a great number of studies have evaluated 
its use as an iron status indicator.  For the purpose of this literature review, only studies 
examining circulating TfR in infants and children will be examined.  A significant 
limitation to comparing these studies, however, is the lack of standardization of reference 
intervals between different assay systems (33-36). Yeung et al. compared three distinct 
ELISA methods and determined differences among methods were so large comparison of 
circulating TfR values from different assays was unacceptable (36).  More recently, a 
fully automated circulating TfR immunoturbidimetric assay showed good comparison to 
two ELISA assays (r>0.8) and it was determined results of the three could be compared 
(37). Because published studies have not necessarily used methods that are comparable, 
extreme care in interpreting and comparing results is required.  For the purpose of this 
review, the circulating TfR assay method will be documented for each study when 
possible. 
One of the first studies of circulating TfR in children and infants was reported in 
1997. Yeung and Zlotkin examined plasma TfR and plasma ferritin concentrations and 
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the log TfR:ferritin ratio in 485 healthy, middle class urban infants aged 8 to 15 months 
(38). Plasma TfR was measured using an in-house ELISA assay method. The mean 
plasma TfR concentration and log TfR:ferritin ratio were 4.4 ± 1.1 mg/L and 6.2 ± 1.1 
μg/μg respectively.  The authors did not find an association between plasma TfR and 
Hgb, FEP, or plasma ferritin, which they report could be attributed to the normal Hgb 
concentrations of the population (12.68 ± 1.48 g/dL).  However, other research has 
shown associations between these iron markers (39-40). 
 Detailed statistical analysis using circulating TfR and ferritin was defined by 
Punnonen et al. They examined the use of serum TfR and serum ferritin in the 
identification of true IDA versus anemia of chronic disease and reported the circulating 
TfR:ferritin ratio was a good indicator of iron deficiency (AUCROC 0.98) (41).  However, 
this ratio was not statistically better than circulating TfR alone. Other possibilities of 
combining circulating TfR and ferritin were evaluated and the logarithmic transformation 
of the ferritin and the calculation of the circulating TfR:log ferritin ratio provided a better 
statistical model (AUCROC 1.00).  Based on these results, the ratio of circulating TfR to 
ferritin is now often termed serum TfR-F index and is calculated using circulating 
TfR:log ferritin.  
 In 1998 Kling et al. observed the change in plasma ferritin, plasma TfR and 
erythropoietic activity of 22 infants aged 0 to 7 months consuming iron-fortified formula 
(42). Plasma TfR was determined by the QuantikineTM IVDTM Human TfR Immunoassay 
kit (R&D Systems, Minneapolis, MN).  Mean plasma TfR levels varied (p<0.002) over 
the first 7 months of life with the lowest plasma TfR levels at 1 month (0.88 ± 0.03 mg/L) 
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and the highest at 4 months (1.97 ± 0.84 mg/L).  Plasma ferritin levels decreased with 
postnatal age (p<0.0001).  Plasma TfR levels were positively associated with plasma 
EPO (z coefficient 3.22; p<0.001) but negatively associated with Hgb (z coefficient; -
2.60 p< 0.009) and plasma ferritin (z coefficient -4.62; p<0.0001).  The authors speculate 
that during the first months of life, increases in plasma TfR levels reflect the increased 
use of iron in the process of erythropoiesis. 
 In a group of 36 healthy 1 year-old infants with no history of chronic disease, 
Virtanen et al. found a mean serum TfR concentration of 7.8 mg/L (95% reference 
interval: 4.5-11.1 μg/L) using the Ramco Laboratories ELISA kit (Ramco Laboratories, 
Inc, Houston, TX) (39). The serum ferritin geometric mean was 24μg/L (95% reference 
interval 9-62 μg/L) and the geometric mean serum TfR:ferritin ratio was 316 µg/µg (95% 
reference interval 94-1059 µg/µg). There was an inverse correlation between serum TfR 
and log serum ferritin concentration (r=-0.50; p=0.002) and between serum TfR 
concentration and MCVs (r=-0.-0.40; p=0.02).  When combined with other age groups in 
a multiple linear regression model, the best predictors of serum TfR concentration were 
log serum ferritin (p<0.0001) and serum iron (p=0.004).  This study is a good model for 
our current study because the same TfR assay was utilized and the lifestyle patterns of the 
subjects were similar.  Fifty percent of the infants were breast fed at least 6 months, 19% 
for 9 months and 8% for 11 or more months.  All but 3 infants were given iron-fortified 
formula when not exclusively breastfeeding.  None of the infants had a serum ferritin of 
<12μg/L. 
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 Choi et al. measured circulating TfR concentration in a variety of age groups of  
Korean children to examine changes in circulating TfR over time (43).  In total, 849 
healthy nonanemic subjects aged 0 to 62 years were examined.  Serum TfR was 
measured using the IDeATM sTfR kit (Orion Diagnostica, Espoo, Finland). Mean serum 
TfR concentrations for neonates less than 5 minutes of age, infants aged 4 to 24 months, 
and young children aged 3 to 7 years were 4.95 ± 1.24, 4.51 ± 1.12, and 3.02 ± 0.76 mg/L 
respectively.  The serum TfR concentrations were significantly higher in infants 
compared to young children (p<0.01).  The conclusion was made that circulating TfR 
levels decrease with age even during the early years of life. 
Circulating TfR and log circulating TfR:ferritin was measured in 716 healthy, low 
to low-middle class Chilean infants aged 4 to 15 month(40). Fourteen percent of the 
children had abnormal Hgb (<11.0g/dL) and 46.9% had abnormal serum ferritin 
(<10μg/L). Circulating TfR was measured using an in-house ELISA method.  The 
median circulating TfR was 8.5 mg/L (95% CI 5.9-13.5) and the geometric means for 
serum ferritin and log circulating TfR:ferritin were 10 μg/L (range 5-22μg/L) and 951 
μg/μg (range 398-2356μg/μg) respectively.  Significant correlations were observed 
between circulating TfR, log circulating TfR:ferritin, log serum ferritin and regular 
laboratory indicators of iron status including Hgb, MCV, FEP, serum iron, and TIBC.  As 
the severity of iron deficiency progressed, the mean circulating TfR concentration 
increased (p<0.00001, ANOVA), however, there was no change in circulating 
TfR:ferritin ratio.  Like Punnonen et al., Olivares et al. observed circulating TfR and 
circulating TfR:ferritin had better sensitivity and specificity for detecting ID compared to 
 23
serum ferritin (AUCROC 0.75 ± 0.02, 0.72 ± 0.02, and 0.67 ± 0.03 for circulating TfR, 
circulating TfR:ferritin ratio and serum ferritin respectively). Unlike Punnonen et al., 
Olivares et al. did not see an increased benefit of using the circulating TfR:ferritin ratio 
compared to circulating TfR alone. 
 In 301 healthy children aged 6 months to 18 years, Suominen et al. found no 
significant gender effect in serum TfR concentrations in infants and children up to 10 
years of age using an automated immunoturbidimetric assay (IDeA® sTfR-IT; Orion 
Diagnostica)  (p=0.37) (44).  There was an age-related decrease in serum TfR 
concentration when children between 0.5 to 4 years were compared to those 4 to10 years 
of age (p<0.001). Age-based reference limits for the assay were derived and set at 1.5-3.3 
mg/L for children aged 6 months to 4 years and 1.3–3.0 mg/L for children aged 4 to 10 
years.  
In a study to evaluate the diagnostic usefulness of circulating TfR in recognizing 
iron deficiency without anemia, Lopez et al. examined a total of 251 healthy children 
(45).  Two hundred six subjects had normal iron status and 45 had ID (ferritin <10μg/L in 
children 1 to 5 years and <12μg/L in those 6-10 years old). Serum TfR was measured by 
the QuantikineTM IVDTM-Human sTfR ELISA kit (R&D Systems, Minneapolis, MN).  
The mean serum TfR of the iron sufficient group (1.93mg/L ± 0.41) was significantly 
lower than the iron depleted group (2.28mg/L ± 0.5) (p=0.001).  The serum TfR:ferritin 
ratios for the iron sufficient and iron depleted groups were 80 μg/μg ± 36.8 and 567 
μg/μg ± 358 (p=0.001) respectively.  The serum TfR-F Index for the iron sufficient and 
iron depleted groups were 1.38 μg/μg ± 0.34 and 4.1 μg/μg ± 2.1 (p=0.001) respectively. 
 24
Serum TfR was the only biomarker that showed a significant difference between the two 
groups of children.  The cut off levels for diagnostic purposes were defined as 2.5mg/L 
for serum TfR, 175 μg/μg for serum TfR:ferritin ratio, and 2 μg/μg for serum TfR:log 
ferritin.  
From this review it is evident several approaches to reporting circulating TfR and 
ferritin have been utilized as well as different assay methods.  Regardless of these 
differences, there are three consistent findings.  1) Circulating TfR decreases with age.  
Theories for this occurrence include both increased cellular iron needs during growth and 
development and increased erythropoesis.  2) Circulating TfR levels are higher in iron 
depleted individuals compared to iron sufficient individuals.  This agrees with the 
original findings that circulating TfR only increases after iron stores are depleted.  3) 
There are no gender differences in circulating TfR concentration.  
Controversy still exists regarding the correlations between traditional iron status 
markers, circulating TfR, ferritin, and the various proposed ratios.  Some researchers 
report strong correlations while others report none at all.  Also, the difference in reporting 
circulating TfR:ferritin ratios makes comparing studies difficult.  
Acknowledging the need to develop a practical iron surveillance system, Cook et 
al. proposed a formula to express body iron in milligrams per kilogram body weight (33).  
Derived from calculated iron stores from serial phlebotomy, the equation is based on a 
logarithmic circulating TfR:ferritin ratio.  Positive calculated values indicate storage iron 
while negative values indicate tissue iron deficiency.  Although the use of this equation is 
still limited by circulating TfR standardization, the potential for expressing body iron on 
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the basis of body weight is promising.  Perhaps the largest advantage is that expressing 
body iron based on weight could potentially eliminate the need for absolute reference 
values that are often inappropriate for target populations.  
In 2005, the body iron equation was used to evaluate the iron status of 800 
Bolivian children less than the age of 5 (46).  The mean body iron stores were 1.71 ± 4.53 
mg/kg and 11.8% of the children had tissue iron deficits, consistent with anemia.  
Specifically, children less than 2 years old had a high prevalence of tissue iron deficit, but 
a linear increase in body iron with age was observed and the average total body iron of 
children 4 years old was 3.85 mg/kg. 
 
Clinical Presentations and Consequences f Iron Deficiency and Iron Deficiency Anemia 
 Commonly known physical symptoms of IDA include fatigue, dizziness, 
headaches, pallor, brittle nails, angular stomatitis, glossitis, and pica. Decreased aerobic 
capacity, work capacity, immune function, and school function as well as increased rates 
of infection and impaired temperature regulation are also well documented.  Specifically 
related to young children, iron status is thought to affect cognition and behavior.  The 
exact relation to iron and brain development is unknown; however, it is thought that 
inadequate iron during early life may lead to alterations in neurotransmitter metabolism 
and myelination in the brain (47-48).  Controversy still exists regarding the timing and 
level of iron deficiency required to identify cognitive delay as well as the duration of 
delay after repletion. 
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 In two well known developmental studies in which iron treatment therapy was 
implemented, a decrease in Hgb below the conventional cutoff limit for anemia was 
necessary to significantly affect mental and psychomotor development scores (49).   In 
one of the studies, children with chronic IDA (≥3 months) had significantly lower mental 
and motor test scores on the Bayley’s Scales of Infant Development than those with IDA 
of shorter duration (50). In the second study, IDA infants maintained closer contact with 
caregivers during play and showed less pleasure and delight (51).  They were also more 
wary or hesitant, experienced more fatigue, and were less vocal.    
In support of these trials, other iron intervention studies show that despite 
improved iron status, formerly anemic infants may be unable to improve their 
psychomotor performances to the level of nonanemic controls (49).   In the longest trial 
to date, children 11 to 14 years of age who had severe (Hgb<10.5g/dL) and chronic (≥3 
months) IDA during infancy scored lower on measures of overall mental and motor 
functioning (52). The previously IDA children were also more likely to repeat a grade, be 
referred for special services, and demonstrate anxiety, depression, social problems, and 
attention problems.  It should be noted other variables such as unidentified nutrient 
deficiencies, parental intellectual and emotional limitations, or environmental 
disadvantages both early and late may confound results at such a late age.  
   
Influential Factors Affecting Iron Deficiency and Iron Deficiency Anemia  
 Late infancy and early childhood are often cited as high risk periods for the 
development of ID and IDA (53-56).  Influential factors to be discussed in this review 
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include: gestational risks, birth weight and rate of growth during early life, gender, 
dietary iron intake, height-for-weight status, and preschool/daycare attendance.   
Most infants are born with sufficient iron stores to support infant growth and 
development until approximately 6 months of age (56-58).  However, several high-risk 
gestational conditions including gestational diabetes (GDM), intrauterine growth 
restriction (IUGR), and maternal binge drinking have been documented to decrease infant 
iron status at birth and increase ID and IDA risk.  Sixty-five percent of infants born to 
mothers with GDM in a 1990 study had abnormal serum iron profiles characterized by 
decreased ferritin and TIBC and increased FEP (59).  Abnormally higher Hgb 
concentrations were observed in IUGR infants (16.4 g/dL) compared to appropriate 
weight for gestational age (AGA) infants (15.7 g/dL) (p<0.001) in 1999 (60).  Both 
studies cited intrauterine hypoxia and compensatory Hgb synthesis as possible 
mechanisms.  In 2007 Carter et al. reported maternal binge drinking was associated with 
a significantly higher incidence of IDA at 12 months of age and proposed prenatal 
alcohol exposure may disrupt transport of iron across the placenta (61). 
 Even if the child is born without a high-risk gestational condition, other factors 
such as birth weight and growth rate early in life may affect iron status because of the 
important role iron plays in growth.  Wharf et al. observed birth weight had positive 
effect on ferritin (p<0.001) at 4 months of age (62) and both Persson et al. and Sherriff et 
al. noted a positive association between birth weight and ferritin levels at 12 months of 
age (63-64).  Regarding growth during the first year, Michaelsen et al. reported a 
negative association between knee-to-heel growth velocity and serum ferritin (p=0.006) 
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at 12 months of age (65).  Sherriff et al. reported  rapid growth between 8 and 12 months 
of age was associated with depleted ferritin levels (r=-0.154; p=0.004), but not between 
12 and 18 months (r=-0.07; p=0.168).  Using serum TfR as an indicator of iron status, 
Thorsdottir et al. saw a positive association between serum TfR and linear growth 
(r2=0.14; p=0.04) (54). 
 Gender differences among infants in relation to iron markers have been described 
by Domellof et al (58).  After adjustment for birth weight and postnatal weight gain, at 4, 
6, and 9 months, boys had lower Hgb (p=0.013), MCV (p<0.001), and ferritin (p<0.001) 
and higher zinc protoporphyrin (ZPP) (p=0.007) and plasma TfR (p<0.001) compared to 
girls (58).  The gender difference in MCV and ZPP remained evident at 9 months of age 
even after controlling for iron supplementation and growth variables. The authors 
speculated that these results were due to possible hormone-mediated or genetic 
differences in iron metabolism between young males and females.  Other studies, 
however, show no difference in circulating TfR concentration between sexes in children 
(38-39,44). 
 Dietary iron intake during infancy is important after 4 to 6 months of age when 
fetal stores are depleted (66).  A recent US study observed that young children 
exclusively breastfed for 6 months were at increased risk for ID (67) and a UK study 
found  infants consuming iron-fortified formula were better protected from ID and IDA at 
8 and 12 months of age compared to those consuming cows’ or breast milk (68).  As 
young children transition to the family diet pattern, the need to monitor their dietary 
intake for insufficiency becomes even more important (69).  Foods and nutrients found to 
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be inversely associated with iron status during these transition years include cheese, 
butter, calcium, tea, and cows’ milk (54,65, 70-72).  Vitamin C, iron, fish, and meat 
intakes have been positively associated with iron status (54,71).  In a study to evaluate 
the nutritional quality of childrens’ diets in the second year of life, Picciano et al. found 
only 40% of 12-month-olds and 20% of 18-month-olds met daily iron intake 
requirements (73).  However, the 1989 Recommended Dietary Allowance (RDA) for iron 
was used to assess the mean iron intake in this population.  The current practice to assess 
the adequacy of population nutrient intake is to use the Estimated Average Requirement. 
 In a very recent national analysis of ID risk in the United States, both daycare 
attendance and weight-for-height status were independently associated with ID in young 
children after controlling for race/ethnicity and interview language (10).  Specifically, 
20.3% of overweight children between the ages of 1 and 3 years compared to 7.1% of 
normal weight children were iron deficient.   Also, 5.2% of children attending daycare 
versus 10% of those not attending daycare were iron deficient.  The authors stated 
prolonged bottle-feeding and the subsequent link to increased juice intake during 
childhood were cited as possible causes for the association between overweight and ID.  
Higher quality diets at daycare that protect against poorer family nutritional practices 
were cited as possible mechanisms behind the association between daycare attendance 
and ID association.
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CHAPTER 3:  IRON STATUS AND DIETARY AND ANTHROPOMETRIC RISK 
FACTORS IN US TODDLERS 
This work will be submitted for publication in the American Journal of Clinical Nutrition 
 
Abstract 
Iron deficiency (ID) is a common problem among US children but diagnosis 
requires four tests.  An equation using only the logarithmic ratio of circulating transferrin 
receptor to ferritin has been proposed to quantify body iron in adults, however, its 
application in children is limited.  Our objective was to determine the body iron of 
middle-class US toddlers using this equation and to compare calculated body iron to 
dietary and anthropometric covariates previously associated with ID. Eighty-six healthy, 
18-to 36-month-old toddlers were recruited. Anthropometric, dietary, and hematological 
data were collected.  Multiple regression analyses revealed dietary calcium intake and 
body mass index negatively influenced body iron, and birth weight, dietary iron intake, 
and energy intake positively influenced body iron. These predictive variables are similar 
to previously reported iron status risk factors.  Our findings support the use of the body 
iron equation as a simple measure of iron status in healthy young children. 
 40
Introduction 
 Iron deficiency (ID) and iron deficiency anemia (IDA) are common problems 
among children in the US and iron is the most common nutrient deficiency worldwide 
(1).  Recent data from the National Health and Nutrition Examination Survey (NHANES) 
IV demonstrated that the prevalence of ID in US toddlers ages 1 to 3 years decreased 
from 9% to 8% in the last decade (2).  However, this prevalence is still far from the 
national goal to reduce ID to less than 5% of 1 to 2 year olds and 1% of 3 to 4 year olds 
by the year 2010 (3).  
 The consequences of ID and IDA can be severe.  Several studies indicate infants 
with chronic IDA have impaired neurodevelopment, decreased language ability, and poor 
fine-motor skills (4-6).  Furthermore, even after treatment, previously IDA children may 
be more likely to repeat a grade, be referred for special services, or demonstrate anxiety, 
depression or attention problems (7).  The exact relation to iron and brain development is 
still unknown; however, it is thought that inadequate iron during early life may lead to 
alterations in neurotransmitter metabolism and myelination in the brain (5-6). 
 Dietary habits and rapid growth during infancy and early childhood are known to 
affect iron status.  Compared to formula fed infants, infants fed breast and cows’ milk at 
8 months of age have poorer iron status at 12 months (8). It is also thought that 
exclusively breast fed infants over 6 months of age may be at increased risk for IDA (9). 
In children aged 12 to 24 months, cows’ milk, cheese, and butter intakes negatively 
affected iron status (10-13) possibly because of the role dietary calcium plays in 
inhibiting iron absorption.  However, iron, vitamin C, fish, and meat intakes positively 
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influenced iron status (11,13).  Rapid growth during the first year of life is also thought to 
decrease iron status and negative associations have been found between growth velocity 
and serum ferritin at 12 months of age (14) 
 Traditionally ID and IDA are diagnosed using a battery of measures including 
ferritin, transferrin saturation, free erythrocyte protoporphyrin and hemoglobin (Hgb).  
Critics cite the limited specificity and sensitivity of these measures along with their 
tendency to be elevated during inflammation as evidence for the need to find better 
indicators (15-18).  A newer marker, circulating transferrin receptor (TfR), has been 
accepted for early ID detection (19-20).  Recently, an equation using circulating TfR and 
ferritin to quantify total body iron as a measure of milligrams iron per kilogram body 
weight has been proposed in adults, however, reports of its use in children are limited 
(16,21-22).   
 The purpose of this study was to determine the iron status of healthy US toddlers 
using Hgb, plasma TfR, plasma ferritin and the calculated total body iron equation, and to 
identify associations between iron status and dietary and anthropometric variables in this 
population. 
 
Subjects and Methods 
Study population 
 Caregivers of subjects were recruited using a targeted phone directory or through 
word of mouth among families who had previously participated in infant nutrition 
research at the University of Kansas Medical Center.  Eighty-six subjects were recruited 
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between the months of July 2006 and March 2007. At the first visit, subject gender, race, 
weight, height (Appendix A), 24-hour dietary recall (Appendix B) and venous blood 
sample were obtained before they were randomized to a milk-based drink that contained 
different levels of nutrients.  To be eligible for the parent study, subjects had to be 18 to 
36 months old and of normal weight, be daily consumers of milk or a milk-based 
beverage, and live with their parent(s). Subjects were ineligible if they were receiving 
breast milk at time of randomization, were from a multiple birth, had an intolerance to 
cows’ milk, were diagnosed with an underlying disease, or had an active infection 0 to 7 
days prior to randomization. Written informed consent was obtained from the caregiver 
before participation in the study (Appendix C).  The University of Kansas Medical Center 
Human Subjects Committee approved the study protocol (HSC#10466). 
Study design 
 A total of three visits were required for the parent study. At each visit, dietary 
recalls were acquired by a registered dietitian who had been trained to use the 3-pass 
method.  Results from the three separate recalls were averaged to improve reliability.  For 
the purpose of this study, only blood drawn at enrollment was used to measure Hgb, 
ferritin, and plasma TfR unless insufficient amounts were obtained, in which case blood 
from the third visit was used.  Measured height and weight also from enrollment were 
used to calculate Body Mass Index (BMI).  A supplemental questionnaire was approved 
by the Human Subjects Committee and mailed to study families in November 2007 
(Appendix D).  Information regarding the mother’s use of supplements before, during, 
and after pregnancy as well as the subject’s birth weight, duration of breast milk and/or 
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formula feeding, age at first food, and use of supplements was obtained using this 
questionnaire. 
Laboratory methods 
 Whole blood was collected in 6 mL sodium-heparin tubes (BD Vacutainer, 
Franklin Lakes, NJ) and centrifuged at 3000 g for 10 minutes at 4ºC.  Plasma was stored 
in 1 mL microcentrifudge tubes at -80ºC.  Both whole blood and plasma samples were 
sent to LabOne laboratories (now Quest Diagnostics, Madison, NJ) daily and analysis of 
Hgb and ferritin was completed at a local Kansas City site using automated analysis. 
 Batches of approximately 32 samples were analyzed in duplicate for plasma TfR 
with an enzyme immunoassay kit (Ramco Laboratories, Inc, Houston, TX) (Appendix E).  
If intra-assay variability was higher than 8.5%, samples were re-run.  The final mean 
intra-assay variability was 4.3 ± 3.1%.  Total body iron was calculated using Cook’s 
logarithmic equation of circulating TfR:ferritin (16). 
Statistical analysis 
Of the original 86 subjects enrolled, dietary intake data were available for 85 
(99%) subjects.  Hemoglobin, plasma ferritin, and plasma TfR concentrations were 
available for 79 (92%), 70 (81%), and 83 (97%) subjects respectively. Seventy-one 
caretakers (83%) returned the supplemental questionnaire. Sixty-nine subjects (80%) had 
all three hematological indicators and fifty-seven subjects (66%) had all data available. 
 Means, standard deviations, and ranges were calculated for descriptive, dietary, 
and hematological data.  The geometric means and exponentiated standard deviations 
were computed for plasma ferritin and TfR:ferritin.  Logarithmic transformation of 
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ferritin was used to create a normal distribution, and Pearson’s Product Moment 
correlations were used for simple correlation analysis.  Student t tests were used to 
compare means and one-way ANOVA was used to compare differences between total 
body iron status groups.  When the results of the ANOVA were significant, identification 
of significant differences between groups was based on Newman-Keuls post hoc test.   
Multiple linear regression analysis was used to evaluate associations between total 
body iron and anthropometric and dietary intake markers.  Previously identified 
covariates considered for the models included calcium, iron and energy intakes, gender, 
race, birth weight, age, BMI, childhood vitamin and maternal prenatal supplement use, 
duration of breast milk and/or formula feeding, and age at first food. Because dietary iron 
and energy intake were highly correlated (r=.480; p<0.01), separate regression models to 
examine total body iron were constructed that included either iron intake or energy 
intake. All statistical procedures were done using Microsoft Office Excel 2007® for 
Windows (Microsoft Corp., Seattle, WA) and SAS® version 9.2 (SAS Institute Inc., Cary, 
NC). Significance was determined by alpha less than 0.05 and all p values were based on 
two-sided tests. 
 
Results 
 All available data (n=69 to 86) were used to generate summary statistics and 
simple correlations.  Only the 57 subjects with a complete set of data were used in the 
final multivariate regression models. Summary statistics of the population are shown in 
Table 2. Birth weight, duration of breast and/or formula feeding, age at first food, and 
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duration of child’s vitamin and/or mother’s prenatal supplementation use were self 
reported. No subject was >85th percentile age for BMI.  Ninety-one percent of the 
mothers who completed the mailed questionnaire reported they consumed a prenatal 
vitamin during their pregnancy. 
 
TABLE 2 Summary statistics of study population1  
Characteristic  Mean SD Min – Max 
Sex     
   male ,  n=45     
   female, n=41     
Age (mo)  25.9 5.9 18.0 - 35.2 
Birth weight (g)  3323 407 2041 – 4354 
Breast fed (mo)  7.0 6.4 0 – 26 
Formula fed (mo)  7.1 4.6 0 – 13 
Age at 1st food (mo)  5.6 1.8 3 – 11 
Weight (kg)  13.0 1.8 8.7 - 17.7 
BMI  16.0 1.0 14.0 - 18.6 
Energy intake (kcal/d)  1184 278 666 – 1771 
Iron intake (mg/d)  8.9 3.6 3.2 - 20.8 
Calcium intake (mg/d)  781 300 291 – 1772 
Mother's PNV intake (mo)  18.6 16.9 0 – 64 
1 Eighty-six values were available for age, weight, and BMI, 85 for energy, calcium, and dietary 
intake, 71 for breast and formula fed and for age at first food, and 70 for mother’s PNV intake 
     
  
Summary statistics of iron status markers are shown in Table 3. Iron deficiency 
and IDA could not be diagnosed according to conventional standards because transferrin 
saturation and free erythrocyte protoporphyrin markers were not available. However, the 
prevalence of low iron storage based on plasma ferritin alone (ferritin <10μg/L) was 7% 
(5 of 70), and the prevalence of abnormal Hgb levels associated with IDA (Hgb 
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<11.0g/dL) was 4% (3 of 79).  Approximately 7% (5 of 69) of subjects had negative body 
iron using the total body iron equation.  No age or gender differences were seen in any of 
the iron status markers, thus, male and females of all ages were grouped together for 
analysis.  Hemoglobin and log plasma ferritin were not correlated (r=0.085), though, both 
Hgb and log plasma ferritin were negatively correlated with plasma TfR (r= -0.306; 
p=0.01 and r= -0.363; p=0.01 respectively). 
 
TABLE 3 Summary statistics of iron status markers1  
Characteristic  Mean SD Min – Max 
Hgb (g/dL)2  12.25 0.8 10.6 - 14.4 
Ferritin  (μg/L) 3  22.22 14.3 3 – 66 
TfR(mg/L)2  6.22 2.0 2.01 - 14.93 
TfR/ferritin (μg/µg) 3  260.21 714.0 65.27 - 4975.37 
TfR/log ferritin (μg/µg)2  5.07 4.2 2.04 - 31.28 
Total Body Iron (mg/kg)2  3.38 2.8 -7.24 - 8.35 
1 Seventy-nine values were available for Hgb, 70 for ferritin, 83 for TfR, and 69 for TfR/ferritin, 
TfR/log ferritin and total body iron 
2 mean, SD 
3 geometric mean; exponentiated SD     
 
Dietary intake 
 No subjects consumed less than the Estimated Average Requirement for iron (3 
mg/d).  However, plasma ferritin and total body iron were lower in toddlers who 
consumed less than the Recommended Dietary Allowance (RDA) for iron (7 mg/d) 
compared to those who consumed the RDA (ferritin; p=0.002, total body iron; p=0.008) 
(Figures 1 and 2).   
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FIGURE 1 Mean (±SD) plasma ferritin concentration of toddlers consuming more or 
less than the RDA for iron (p=0.002) 
 
 
 
 
 
 
FIGURE 2 Mean (±SD) total body iron concentration of toddlers consuming more or 
less than the RDA for iron  (p=0.008) 
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 When total body iron was divided into quartiles, dietary iron intake was 
significantly different between the 1st and 2nd and between the 3rd and 4th quartiles 
(Figure 3).   
 
 
 
FIGURE 3  Total body iron quartiles based on dietary iron intake.  Columns bearing 
different letters within a group are significantly different (p=0.0377) based on one-way 
ANOVA model.  Mean (±SE) dietary iron intake for the quartiles were: Q1: 7.32 ± 0.81, 
Q2: 8.80 ± 0.65, Q3: 8.66 ± 0.86, Q4: 10.75 ± 0.96. 
 
 Results from the first multiple regression model are shown in Table 4. Iron intake 
and six other independent variables including calcium intake, race, birth weight, BMI, 
childhood vitamin use, and age at first food were used.  None of the independent 
variables were correlated with each other.  Using this model, 17.7% of the variance in 
total body iron was explained, and dietary iron intake approached significance as a 
predictor of total body iron status (B=0.2002; p=0.0556). 
 
a 
b
c 
b
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TABLE 4 First multiple regression analysis for total body iron (mg/kg)1 
Independent variable2   Parameter Estimate Standard Error P value 
Intercept  3.867 3.690 ― 
Calcium intake (mg/d)  -0.005 0.001 0.0006 
Iron intake (mg/d)  0.2002 0.102 0.0556 
Birth weight (g)   0.0019 0.000 0.0377 
1 Adj. R2 = 0.1771     
2 When added to this model, none of the other variables (race, BMI, childhood vitamin usage, and age at 
first food) were not significant and are not shown 
 
Eighty-nine percent of subjects consumed more than the Adequate Intake (AI) for 
calcium (500 mg/d) and the mean intake was 781 mg/d indicating the overall group was 
at low risk for inadequate calcium intake.  Dietary calcium was negatively associated 
with formula feeding duration (r= -0.295; p<0.01), log plasma ferritin (r= -0.224; p=0.05) 
and total body iron (r= -0.244; p=0.05).   
In the second multiple regression model, dietary energy intake was combined with 
calcium intake, race, birth weight, BMI, childhood vitamin and maternal prenatal 
supplement use, duration of formula feeding, and age at first food to predict total body 
iron status (Table 5).  Using this model, the explained variance in total body iron was 
22.3%.  Dietary calcium was inversely correlated with total body iron (B= -0.006; 
p=0.0006) in this model (Table 5) as well as in the first model (B= -0.005; p=0.0006) 
(Table 4). 
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TABLE 5 Multiple regression analysis model 2 for total body iron (mg/kg)1 
Independent variable2  Parameter Estimate Standard Error P value 
Intercept  1.581 3.902 ― 
Calcium intake (mg/d)  -0.006 0.002 0.0006 
Body Mass Index  -0.262 0.129 0.0478 
Energy intake (kcal/d)   0.004 0.002 0.0157 
1 Adj. R2  = 0.223     
2 When added to this model, none of the other variables (race, birth weight, childhood vitamin 
usage, prenatal vitamin usage, duration of formula feeding, and age at first food) were 
significant and are not shown. 
 
Using Pearson’s Product Moment correlations, the reported duration of formula 
feeding was positively correlated with log plasma ferritin (r=0.296; p=0.02) and total 
body iron (r=0.288; p=0.02) but not to plasma TfR status.  However, these relationships 
were not significant in the multivariate models.  No correlations were found between 
breast feeding and any iron status markers. 
Anthropometric measures 
 Child birth weight was positively associated with Hgb (r=0.263; p=0.02) and 
negatively associated with plasma TfR (r= -0.266; p=0.02). Height was positively 
correlated with energy intake (r=0.230; p=0.05) and vitamin usage (r=0.354; p<0.01), but 
it was not significantly correlated with any iron status markers.  Weight at time of 
enrollment was positively correlated with Hgb (r=0.280; p>0.01) but no other iron 
marker or dietary factor.  In the first multiple regression model (Table 4), child birth 
weight was significantly correlated with total body iron (B=0.0019; r=0.0377).  In the 
second multiple regression model (Table 5), BMI was a significant predictor of total body 
iron (B=-0.262; p=0.0478). 
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Discussion 
 ID and IDA remain common public health problems in United States and the 
current method of identifying ID is subject to a variety of inconsistencies.  The evaluation 
of circulating TfR, ferritin, and ratios of circulating TfR:ferritin and circulating TfR:log 
ferritin have been proposed as sensitive and efficient measures of early ID even in 
children (20, 23-24).  More recently, Cook et al. developed a quantitative equation of 
total body iron using log circulating TfR:ferritin to estimate iron status on the basis of 
body weight rather than absolute values (16). Using Cook’s equation, positive values 
indicate storage iron while negative values indicate tissue iron deficiency.  The mean 
body iron stores in healthy US male and female adults were reported to be 9.89 ± 2.82 
mg/kg and 4.87 ± 4.14 mg/kg respectively (16).  In a group of mildly anemic Bolivian 
children aged 1 to 4 years, total body iron was 1.72 mg/kg (22).  
 The negative correlations observed between Hgb and plasma TfR, and between 
plasma ferritin and plasma TfR are also consistent with previous findings (25).  These 
associations may be largely explained by examining the effect these indicators have on 
one another at the cellular level.  In an individual with adequate iron status, both Hgb and 
ferritin concentrations are within normal ranges.  In the cell, adequate ferritin stores 
saturate iron binding proteins, preventing cellular TfR synthesis and subsequently 
lowering circulating TfR (26).  However, during iron deficiency, ferritin stores are 
depleted and the iron binding proteins are free to promote cellular TfR synthesis. The 
increase in cellular TfR increases circulating TfR. 
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 Our results for circulating TfR and ferritin concentrations in toddlers are similar 
to previous studies that used similar methods.  Virtanen et al. reported serum TfR and 
serum ferritin concentrations of 7.8 mg/L and 24 µg/L in 12-month-old infants (24) while 
we report concentrations of 6.22 mg/L and 22.22 µg/L for plasma TfR and plasma ferritin 
respectively.  Both Virtanen and our results support the observation that circulating TfR 
concentrations are higher in children compared to adults (27). The lower circulating TfR 
concentration among our toddlers compared to Virtanens’ infants may also indicate even 
slightly older children have better iron status.  Differences in the amount of iron required 
for growth and erythropoesis during infancy have been cited possible causes (28) though 
other lifestyle habits including dietary intake and living environment may certainly have 
an effect.  Our results of no gender specific differences in circulating transferrin receptor 
are also similar to previous findings (24,27,29-30). 
 As young children transition from iron-fortified baby foods and infant formula to 
the family dietary pattern, dietary iron intake decreases (31), and it is thought that this 
may lead to a decrease in iron status.  Our results support this hypothesis.  Specifically, 
children consuming less than 7 mg iron per day had poorer iron status than those 
consuming the current RDA.  Also, the significant relationship between dietary iron 
intake and total body iron status in the ANOVA and in one multiple regression model 
support the role of iron intake iron status.   
 Other studies have documented negative associations between cows’ milk and 
calcium consumption and iron status markers (11-13).  Our results support this 
observation and indicate that more than any other factor identified in the study, dietary 
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calcium best predicted iron status.  Specifically, total body iron decreased 0.6 mg/kg for 
every 100 mg increase in dietary calcium intake. This relationship is significant because 
it provides evidence that an excessive intake of foods containing high quantities of 
calcium may not be beneficial for iron status.   
The increase in explained variance using the energy intake multiple regression 
model versus the dietary iron intake model is an interesting concept that deserves further 
exploration.  One explanation may be that children consuming more calories are 
somehow consuming iron from different sources compared to children with lower energy 
intakes. Heme iron, for example, is known to be better absorbed and utilized but is found 
in meat products that have a greater relative energy density compared to non-heme iron 
sources such as vegetables.  A second explanation may be that the nutrient analysis 
system used to compute dietary data may be more sensitive to energy intake compared to 
iron intake.  If, for instance, a child consumed iron-fortified foods such as orange juice, 
cereal, or specialty products, the computer system may more accurately estimate calories 
compared to iron.  Future studies that examine the association between the source of 
dietary iron and energy intake, and child iron status may help answer this question.  
 Unlike previous studies, our multivariate analyses did not indicate that formula 
fed children have better iron status compared to those fed breast or cows’ milk.  
Nonetheless, significant simple correlations were found between formula feeding 
duration and total body iron.  There may be two possible reasons for this discrepancy.  1) 
By eliminating subjects who did not have complete data sets, the analytical power to 
detect differences may have diminished. It is possible with a larger sample size regression 
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models would support significant correlations.  2) The age range of our subjects (18 to 36 
months) is beyond the usual weaning period.  It is possible the dietary habits in early 
childhood outweighed iron intake during infancy so that any effect of formula or breast 
feeding was lost. 
 Higher birth weight has been shown to have an iron-protective effect in early life 
presumably because less catch-up growth is needed (10-11,14).  Our results that children 
with higher reported birth weights had higher Hgb, lower plasma TfR, and better total 
body iron status are consistent with this observation.  This finding is noteworthy because 
it suggests child birth weight, which is influenced by a variety of gestational situations, 
continues to influence iron status at 18 to 36 months of age.   Future studies to examine 
possible reasons for low birth weight, such as gestational age at birth and maternal 
substance use, in relation to long term childhood iron status may help better predict 
which children are at highest risk.  
 The significant negative relationship between child BMI and body iron is 
consistent with previous findings that overweight children may be at higher risk for ID 
and IDA (2).  It may be possible that even though overweight children consume an excess 
of calories, their overall quality of diet and iron intake is worse compared to normal 
weight children.  This increased risk of poor iron status adds to the growing list of risk 
factors associated with childhood weight for length.   
 The iron status of our population using the total body iron equation was higher 
than previously reported for young, anemic Bolivian children (22) but lower than US 
adults (16). This supports the assumption that total body iron is lower among individuals 
 55
with functional iron deficits and that children use relatively higher amounts of iron for 
growth and development and thus have less iron storage.  Our finding that total body iron 
was highly correlated with previously identified iron status risk factors including calcium 
intake, iron intake, BMI, and birth weight strengthens the argument for its use as an iron 
status indicator. It shows, even without traditional measures of iron status, similar trends 
using only the total body iron equation can be seen. However, inconsistencies among 
commercial circulating TfR kits and the subsequent disparities of reported circulating 
TfR concentrations limit the use of this equation. 
 In conclusion, the iron status of our population using Hgb, ferritin, and circulating 
TfR indices was better than national averages.  Dietary and anthropometric risk factors 
previously associated with iron deficiency including dietary calcium and iron intakes as 
well as BMI and birth weight were significant predictors of total body iron.  Our findings 
support the use of the total body iron equation as a simple measure of iron status in 
healthy young children.  
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Appendix B 
 
 
24 Hour Dietary Recall Form 
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Visit:_________
Random #___________________    Date of Intake:____________ DOB:___________ EDC:__________
Time Amount
Intake: Typical      More than Usual          Less than Usual         Why? _______________________________
_________________________________________________________________________________________
Recall:  Reliable     Unable to recall meals?  Unreliable for other reasons?  Why? _______________________
_________________________________________________________________________________________
Vitamin/Mineral/Supplement Use?  __________________________________________________________
Home / Daycare / Babysitter                          Number of people responsible for feeding _______________
Interviewer Initials: _______
24-Hour Dietary Recall Form
Food/Beverage Ingredients/Preparation
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CONSENT FORM 
Intake of A Toddler Drink With Different Amounts of Docosahexaenoic Acid  
 
Protocol # 
Sponsor:  Mead Johnson & Company 
 
INTRODUCTION  
As a parent of a child between 18 and 36 months of age, you are being asked if you will 
permit your child to participate in a study of a milk-based drink that contains a nutrient 
called docosahexaenoic acid (DHA). The study will be conducted at the University of 
Kansas Medical Center by Susan Carlson, Ph.D. and other members of her study team. 
Ninety children will be enrolled in the study.  
 
You do not have to allow your child to participate in this research study. It is important 
that before you make a decision for your child to participate, you read the rest of this 
form. You should ask as many questions as you need to understand what will happen if 
your chlld participates in the study. 
 
BACKGROUND  
Docosahexaenoic acid (DHA) is recognized to be important for infant development. DHA 
is found in all breast milk and has been added to US formulas since 2002. DHA 
accumulates rapidly in the brain until children are at least 2 years of age. After infants 
are weaned from breast milk or formula, their DHA decreases unless they consume 
quite a lot of foods with DHA, particularly some kinds of fish. Chicken, eggs and some 
other animal foods contain DHA as well. Toddlers studied in other countries have lower 
blood levels of DHA than infants fed breast milk or DHA-containing formulas.  There are 
no data for DHA intake or blood levels of US toddlers. 
 
PURPOSE 
The purpose of the study is to determine how a milk-based drink containing constant 
amounts of nutrients but different amounts of DHA will affect the blood level of DHA and 
some of those other nutrients in young children between 18 and 36 months of age.  
 
PROCEDURES 
If you choose to enroll your child in this study after hearing about how the study will be 
conducted, and what you and your child will need to do, you will be given an 
appointment to bring your child to the University of Kansas Medical Center. The 
investigators will work with you to find a time of day that is a good one for his/her 
appointment. 
 
Visit 1 Your child will be weighed and measured at his first appointment at KUMC. A 
blood sample (1/2 teaspoon) will be taken by a person trained to take blood from young 
children. The blood sample will be used to measure the level of DHA and some nutrients 
in blood. The investigators will also review the birth and medical history and any 
medications/immunizations that your child has received within the 7 days before Visit 1. 
You will be given forms on which to fill out the amount of the milk product that your child 
consumes and instructed how to fill out the forms. You will be asked what your child has 
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eaten in the past 24 hours and questioned about your child’s general health. If based on 
the above procedures, your child meets the requirements of the study, he/she will be 
assigned by chance (like the flip of a coin) to receive a milk-drinkwith one of three 
amounts of DHA: a marketed product with no DHA or one of two experimental drinks 
with different amounts of DHA. You will be sent home with the 3 cases of the milk drink 
your child is assigned to and you will be asked to provide him/her with one serving per 
day for the next 2 months. This visit will take approximately 1 hour. 
 
Visit 2 One month after your child enters the study, your will bring your child back to 
KUMC and he/she will be weighed. You will be asked what your child has eaten in the 
past 24 hours and about your child’s general health.  You should let the investigator 
know if your child has been sick or not acting well since his/her last visit.  The 
investigators will collect the forms you have filled out about your child’s milk consumption 
during the past month.  You will be sent home with 3 more cases of the milk your child is 
assigned to and asked to continue providing one serving per day for the next 2 months. 
The visit will last approximately 30 minutes. 
 
Visit 3 Two months after your child enters the study, your child will be weighed. You will 
be asked what he/she has eaten in the past 24 hours and questions about his/her 
general health.  You should let the investigator know if your child has been sick or not 
acting well since his/her last visit as illness can influence the amount of nutrients in 
blood.  A blood sample (1/2 teaspoon) will be taken from your child by a person trained 
to take blood from young children. The blood sample will be used to measure the level of 
DHA and other nutrients in blood. The investigators will collect the forms you have filled 
out about your child’s milk consumption during the past month.  You will be asked to 
complete a product assessment form.  You will return any unused full cans of study 
product to the investigator. The visit will last approximately 1 hour.  
 
RISKS 
Some redness, soreness, or bruising may occur at the site of blood sampling.  There is 
also a very slight risk of infection from blood sampling. Toddlers who cannot drink cows’ 
milk should not enroll in this study. Even toddlers who are able to drink milk may not 
tolerate the drink, however, this is considered to be very unlikely. 
 
NEW FINDINGS STATEMENT 
You will be informed if any significant new findings develop during the course of the 
study that may affect your willingness to allow your child to participate in this study. 
You may request to know what nutrients were in your child’s assigned drink when the 
study is complete. 
 
BENEFITS 
Your child is not expected to benefit from participating in this study. It is hoped that 
additional information gained in this research study may be useful in the growth and 
development of toddlers.  
 
ALTERNATIVES 
Your child does not have to participate in this research study. If you wish to increase 
DHA in your child’s diet, you may do so by serving him/her more foods with DHA. There 
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are also supplements such as fish oil that contain DHA. At least one company has a 
marketed toddler drink that contains DHA and it may be purchased in the Kansas City 
area.  
 
COSTS 
You will not incur any costs because of your child’s participation.   
 
PAYMENT TO SUBJECTS 
You will receive a check for $50 at each visit to the University of Kansas Medical Center 
to cover the costs of transportation and to partially compensate you for your time 
required to participate in the study. If you do not have transportation to come for the visit, 
you may ask the investigators to pay for a cab to and from the appointment and you will 
be given the $50 check, however, the investigators will have to deduct the cost of the 
cab from your next check. There will be 3 regularly scheduled visits over the course of 2 
months.  
 
Your name, address, social security number, and the title of this study will be given to 
the KUMC Research Institute.  This is done so that the Research Institute can write a 
check for study payments.  Payments are taxable income. 
 
DISCLOSURE OF FINANCIAL INTERESTS 
The principal investigator has been paid as a consultant and for program presentation on 
DHA for Mead Johnson Nutritionals (the sponsor).  The University of Kansas Medical 
Center Conflict of Interest Committee monitors this research project to make it less likely 
that these financial interests inappropriately influence how the study is conducted.  
However, you should make your own decision about whether these financial interests 
affect your decision to participate.  If you have any questions about this financial 
relationship, you may discuss them with the investigator or with the Research 
Compliance division at 913-588-5492. 
 
INSTITUTIONAL DISCLAIMER STATEMENT 
Although the University of Kansas Medical Center does not provide free medical 
treatment or other forms of compensation to persons injured as a result of participating 
in research, such compensation may be provided under the terms of the Kansas Tort 
Claims Act.  If you believe your child has been injured as a result of participating in 
research, you should contact the Office of Legal Counsel, University of Kansas Medical 
Center, Kansas City, KS 66160-7101. You do not give up any rights by signing this form. 
In the event you believe that your child has suffered any physical injury as the result of 
his/her participation in the research program, you may contact Dr. Susan Carlson, 913-
588-5359, who can review the matter with you and provide further information on how to 
proceed. 
 
CONFIDENTIALITY AND PRIVACY AUTHORIZATION 
Names of subjects or information identifying subjects will not be released without written 
permission unless required by law.  Study data will be shared with the sponsor, but you 
will not be identified. Efforts will be made to keep your child’s personal information 
confidential.  Researchers cannot guarantee absolute confidentiality.  If the results of this 
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study are published or presented in public, information that identifies your baby will be 
removed.  
 
The privacy of your child’s health information is protected by a federal law known as the 
Health Insurance Portability and Accountability Act (HIPAA).  If you choose to allow your 
child to participate in this study, you will be asked to give permission for researchers to 
use and disclose your baby’s health information that is relevant to the study.    
 
Your baby’s study-related health information will be used at KU Medical Center by Dr. 
Carlson, members of the research team, the KU Hospital Medical Record Department, 
the KUMC Research Institute and officials at KUMC that oversee research, including the 
KUMC Human Subjects Committee, and other committees and offices that review and 
monitor research studies.   
 
Dr. Carlson and her group may share information about you and your baby with 
representatives of Mead Johnson (the sponsor of the study), the U.S. Food and Drug 
Administration (FDA), and U.S. agencies that govern human research (if and when 
regulatory compliance issues arise).  Your child’s information may be shared in order to 
analyze and confirm the results of the study.  
 
Some of the persons or groups that receive your baby’s study information may not be 
required to comply with HIPAA privacy laws.  You and your child’s information may lose 
its federal protection if those persons or groups disclose it.   
 
Permission granted on this date to use and disclose your child’s health information 
remains in effect indefinitely.  By signing this form you give permission for the use and 
disclosure of your child’s information for purposes of the study at any time in the future. 
 
QUESTIONS 
You have read the information in this form. Dr. Carlson or her associates have answered 
your question(s) to your satisfaction.  You know if you have any more questions after 
signing this you may contact Dr. Carlson or one of her associates at (913) 588-5359.  If 
you have any questions about your child’s rights as a research subject, you may call 
(913) 588-1240 or write the Human Subjects Committee, University of Kansas Medical 
Center, 3901 Rainbow Blvd. MSN 1032, Kansas City, KS 66160. 
 
SUBJECT RIGHTS AND WITHDRAWAL FROM THE STUDY 
Your permission to allow your child’s participation in this study is voluntary and the 
choice not to participate or to quit at any time can be made without penalty or loss of 
benefits.  Not participating or quitting will have no effect upon the medical care of 
treatment your child receives now or in the future at the University of Kansas Medical 
center.  The entire study may be discontinued for any reason without your consent by 
the investigator conducting the study or by the sponsor of the study.   
 
You have a right to change your mind about allowing the research team to have access 
to your child’s health information. To cancel your permission you must send a written 
request to Dr. Carlson at the University of Kansas Medical Center, Dept. of Dietetics and 
Nutrition, Mail Stop 4013, 3901 Rainbow Boulevard, Kansas City, KS 66160. If you 
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cancel permission to use your child’s health information, he/she will be withdrawn from 
the study and the researchers will stop collecting information about him/her. The 
researchers and the sponsor may continue to use and share information that was 
gathered before your cancellation. 
 
CONSENT 
Dr. Carlson or her associates have given you information about this research study.   
They have explained what will be done and how long it will take.  They explained the 
inconvenience, discomfort and risks that may be experienced during this study.   
 
By signing this form, you give your permission for your child to participate in 3 visits at 
KUMC.  If you choose not to sign this form, your child will not be able to participate in the 
study.   
  
You voluntarily consent to allow yourchild to participate in this research study.  You have 
read the information in this form and have had an opportunity to ask questions and have 
them answered.  You  will be given a copy of the signed form to keep for my 
records. 
 
 
____________________________________    
Type/Print  Name of Subject’s Parent or Guardian      
 
__________________________________  _________ __________________ 
Signature of Subject’s Parent or Guardian Time   Date 
 
 
____________________________________ 
Type/Print Name of Person Obtaining Consent 
 
____________________________________  __________________ 
Signature of Person Obtaining Consent    Date 
 
 
 
Type/Print Name of Witness 
 
____________________________________  __________________ 
Signature of Witness       Date 
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Prenatal Iron and Infant Feeding Questionnaire 
 74
 
 
 
Infant & Toddler Nutrition Research Clinic 
 
KU Dietetics & Nutrition 
Mailstop 4013 
3901 Rainbow Boulevard 
Kansas City, Kansas 66160-7200 
 
Dear Parents, 
 
 You are receiving this letter because your child participated in a clinical 
research trial of a DHA study beverage when he/she was a toddler.  Although the 
study is completed, we are still investigating several key nutrients using your 
child’s blood sample(s). 
 
 One of the nutrients we are examining is iron.  Previous research has 
shown iron is critical for healthy development and a young child’s iron status may 
be linked to both prenatal and postnatal care.  If you are willing, we would like to 
ask a few questions on the following page about the pregnancy of your toddler as 
well as your toddler’s dietary intake as an infant. 
 
 The completion of the questionnaire is completely voluntary and you are 
not required to return it if you feel uncomfortable providing this information.  
However, any information received from this survey will be very helpful in 
understanding the iron status of children who participated in the study. 
 
 Thank you for your support of infant research at KU.  We appreciate the 
time and dedication you have shown to helping us understand the health needs 
of children.  And as always, you may call at anytime if you have any questions or 
concerns. 
 
 
     Thank you and happy holidays, 
 
     Elizabeth Kerling, RD 
 
     Elizabeth Kerling, RD 
     Research Assistant and Masters Candidate 
     Phone: 913-945-6649 
     Fax: 913-588-5309    
     Email: ekerling@kumc.edu  
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Toddl er Nutriti on Questi onnaire 
Dat e:  
  
1.
 
Pl ease circl e yes or no t o i ndi cat e if t he f oll owi ng suppl ements were consumed duri ng t he pregnancy of your 
st udy t oddl er.  If t aken, pl ease provi de t he approxi mat e dat e t hese suppl ements were st art ed and st opped 
︵ mont h and year will be fi ne︶ . Al so, pl ease i ndi cat e how frequentl y t hey were t aken. 
 
 Prenat al vit ami n: 
   Yes No  St art Dat e:  St op Dat e:  Frequency:︳︳
︳︳
 
    
 Iron suppl ement: 
 Yes No  St art Dat e:  St op Dat e:  Frequency: ︳︳
︳︳
 
  
 Ot her: ︵ Pl ease st at e what it was︶  
 
     St art Dat e:     St op Dat e:︳︳
︳︳
︳︳
︳
 
     Frequency: ︳︳
︳︳
︳︳
︳
 
      
     St art Dat e:   ︳︳
︳︳
 St op Dat e:   
       Frequency: ︳︳
︳︳
︳︳
︳︳
︳︳
︳︳
 
 
2. Pl ease circl e if your t oddl er was breast or f or mul a f ed as an i nf ant ︵ or bot h︶ .  For each, pl ease provi de t he 
approxi mat e st art and st op dat e ︵ mont h and year will be fi ne︶ . 
 Breast: 
 Yes No  St art Dat e:  St op Dat e:︳︳
︳︳
︳︳
︳︳
 
  
 For mul a: 
 Yes No  St art Dat e:  St op Dat e:   For mul a Name:︳︳
︳︳
︳
 
 
3.
 
Has your chil d ever consumed any vit ami ns, mi neral s, or suppl ements on a regul ar basi s?  If yes, pl ease provi de 
t he name and approxi mat e dat es as well as durati on and frequency.   
  
 Yes No  Name:   St art Dat e:  St op Dat e:   
       Frequency:   
  
4.
 
When was f ood first i ntroduced t o your st udy t oddl er? ︵ age i n mont hs︶  
  
 
 
5.  How much di d your son or daught er wei gh at birt h? 
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Procedure for Circulating Transferrin Receptor Analysis 
 77
Procedure taken from insert of Enzyme Immunoassay for quantifying Human 
Transferrin Receptors in Serum or Plasma (Catalog #TFR-94) 
 
Ramco Laboratories, Inc 
4507 Mt. Vernon 
Houston, TX 77006 
 
1. Remove plasma samples from -80ºC freezer and allow to thaw 
2. Remove the necessary strips from the packet and place in Microwell Frame (any 
unused strips must be returned to and resealed in the ziplock foil packet, returned to 
2-8ºC and used in 6 weeks) 
3. Prepare a 1:100 dilution of each patient sample and Control by dispensing 1ml of 
Sample Dilutent into a test tube and adding 10μl of patient serum or plasma or 
Control.  Mix thoroughly.  DO NOT dilute standards 
4. Pipette 50μl of each diluted patient sample and control, in duplicate, into individual 
wells 
5. Pipette 150μl of HRP-conjugate into all individual wells containing samples, controls, 
and standards 
6. Seal the microwell strips with the self-adhesive plastic film and place on a rotating 
table and mix for 10 minutes at 190nm or rotate by hand, pressing the frame firmly 
against the counter to avoid sloshing, to ensure mixing of the HRP-conjugate with the 
samples, controls, and standards.  Allow reaction to proceed for an additional 2 hours 
(no rotation) at room temperature upon completion of mixing 
7. Prepare the substrate solution: calculate the amount of substrate solution needed by 
multiplying 0.2ml by the number of wells in the assay run plus 0.5-1ml dead volume.  
Mix equal volumes of TMB substrate solution A and TMB substrate solution B just 
prior to addition of the microwells.  This should be used within 30 minutes of 
preparation. 
8. After the 2 hours incubation, remove plastic film, invert the plate, and dump the 
contents of the microwell strips.  Tap the plate dry on absorbent pad or paper towels.  
Wash the wells with the prepared washing solution (wash solution 5X in 250ml 
graduated cylinder QS to 250ml) using a plate washing device or by using the wash 
bottle to flood the wells and then invert and dump the contents of the wells.  The 
 78
wells should be washed a total of 3 times, tapping dry between each wash.  After the 
final wash, make sure the wells are completely empty 
9. Pipette 200μl of substrate solution into each well containing samples, controls, and 
standards, and incubate in the dark at room temperature for 30 minutes.  A blue color 
should develop in those wells containing TfR 
10. Stop the color reaction by pipetting 50μl of acid stop solution into the wells and mix 
briefly to remove any air bobbles 
11. Read the absorbance of each well at 450nm using a microplate reader.  It is 
recommended that the reader be zeroed using blanks prepared with 200μl of substrate 
solution and 50μl acid stop solution 
